Efficacy results achieved with TYMLOS were
continued after transitioning to alendronate1,2

New vertebral fractures: Risk reduction achieved with TYMLOS
continued after transitioning to alendronate1,2

A 25-month analysis* demonstrated 87% RRR in new vertebral fractures with TYMLOS/alendronate (fracture incidence 0.6%) vs placebo/alendronate (fracture incidence 4.4%) (P<0.0001) and 3.9% ARR2

Percentage of postmenopausal women with osteoporosis with new vertebral fractures at 43 months1†

Percentage of postmenopausal women with osteoporosis with new vertebral fractures graph

Data included 18 months of TYMLOS or placebo, followed by 1 month of no treatment, then 6 months on alendronate.2

Data included 18 months of TYMLOS or placebo, followed by 1 month of no treatment, then 24 months on alendronate.3

P<0.0001.1

Results reported in the modified ITT, which included patients who had both pretreatment and posttreatment spine radiographs.1

The primary and secondary efficacy endpoints for the extension study were at 25 months. The 43-month data are exploratory endpoints.1

The primary and secondary efficacy endpoints for the extension study were at 25 months. The 43-month data are exploratory endpoints.1

At least 6x fewer women in the TYMLOS/alendronate group experienced new vertebral fractures
versus those in the placebo/alendronate group at 43 months1

See nonvertebral fracture dataMinus iconPlus icon

Nonvertebral fractures: Risk reduction achieved with TYMLOS continued
after transitioning to alendronate1,2

A 25-month analysis* demonstrated 52% RRR in nonvertebral fractures with TYMLOS/alendronate
(fracture incidence 2.7%) vs placebo/alendronate (fracture incidence 5.6%) (P=0.017) and 2.9% ARR2

Cumulative incidence of nonvertebral
fractures over 43 months1‡

Cumulative incidence of nonvertebral fracture graph

Results reported in the extension study ITT population, which included patients randomized in the efficacy study.1

Data included 18 months of TYMLOS or placebo, followed by 1 month of no treatment, then 6 months on alendronate.2

Nonvertebral fractures excluded those of the sternum, patella, toes, fingers, skull, and face, and those associated with high trauma.1

Data included 18 months of TYMLOS or placebo, followed by 1 month of no treatment, then 24 months on alendronate.3

P=0.038.1

P-value based on the log-rank test.1

The primary and secondary efficacy endpoints for the extension study were at 25 months. The 43-month data are exploratory endpoints.1

Results reported in the extension study ITT population, which included patients randomized in the efficacy study.1

Data included 18 months of TYMLOS or placebo, followed by 1 month of no treatment, then 6 months on alendronate.2

Nonvertebral fractures excluded those of the sternum, patella, toes, fingers, skull, and face, and those associated with high trauma.1

Data included 18 months of TYMLOS or placebo, followed by 1 month of no treatment, then 24 months on alendronate.3

P-value based on the log-rank test.1

P=0.038.1

The primary and secondary efficacy endpoints for the extension study were at 25 months. The 43-month data are exploratory endpoints.1

See change in BMDMinus iconPlus icon

BMD increases achieved with TYMLOS continued after transitioning to alendronate1,2

In a 25-month analysis,* significant increases in BMD at the lumbar spine, total hip, and femoral neck achieved
with TYMLOS at 18 months were continued after transitioning to alendronate (P<0.0001 at all sites)2

Patients who transitioned from TYMLOS to alendronate achieved at least a 2-fold increase in BMD versus placebo to alendronate at these sites at 43 months1

Patients who transitioned from TYMLOS to alendronate achieved at least a 2-fold increase in BMD versus placebo to alendronate at these sites at 43 months1

Average percentage change from baseline in BMD in postmenopausal women osteoporosis graph

Mean percent change from baseline in BMD in postmenopausal women with osteoporosis at 43 months1†

Data included 18 months of TYMLOS or placebo, followed by 1 month of no treatment, then 6 months on alendronate.2

Data included 18 months of TYMLOS or placebo, followed by 1 month of no treatment, then 24 months on alendronate.3

P<0.0001.1

Results reported in ITT population, which included patients enrolled in the extension study; mean percentage change in BMD was LOCF.1

BMD captured with DXA scans.1

The primary and secondary efficacy endpoints for the extension study were at 25 months. The 43-month data are exploratory endpoints.1

Learn more about Together
with Tymlos

offerings and
the savings card

References: 1. Data on file. Radius Health, Inc; Waltham, MA. 2. TYMLOS® [prescribing information]. Waltham, MA: Radius Health, Inc; 2017. 3. Cosman F, Miller PD, Williams GC, et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc. 2017;92(2):200-210.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2018 Radius Health, Inc.   All rights reserved.    04/18.   TYM-US-01391

This site is intended for HCPs in the United States.
TYMLOS is a registered trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2018 Radius Health, Inc.
All rights reserved. 04/18.
TYM-US-01391

Back to Top